12
Risk-Based Equipment Qualification MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 1 www.ispe.org/PE_Online_Exclusive ©Copyright ISPE 2007 This article presents an efficient cooperative approach to Commissioning and Qualification (C&Q) for manufacturing equipment and covers the entire life cycle for the specification, design, manufacture, installation, commissioning, qualification, operation, and maintenance of the equipment in a risk- based approach. This article reflects the current status of the work in progress conducted by the GAMP Italia Equipment Validation Workgroup. The main topics covered in the article are: holistic risk-based approach covering business, safety, and quality risks involvement of the supplier in the risk management process and risk analysis support from the supplier in the C&Q activities (risk-based) team building time savings • trends good engineering practice Risk-Based Equipment Qualification: A User/Supplier Cooperative Approach by GAMP Italia - Equipment Validation Workgroup: Sandro De Caris, Marco Bellentani, Beny Fricano, Carlo Bestetti, Marco Silvestri, and Barbara Testoni GAMP Italia and Equipment Validation Group G AMP Italia is a local Community of Practice that was introduced to the ISPE community in December 2005, during the ISPE Milan Conference. The mission of GAMP Italia is to improve the communication among users, suppliers, consultants, regulatory authorities, and academia, helping life sciences companies streamline their validation processes through a more consistent application of good practices and the GAMP guidance on both the supplier’s and user’s side. GAMP Italia operates in accordance with the general objectives of the International GAMP Forum and reports to the GAMP Eu- rope Steering Committee, like other regional groups (GAMP Nordic, GAMP D-A-CH, and GAMP Francophone). The Equipment Validation Group is the first working group started within GAMP Italia and is composed of members coming from equip- ment manufacturers, consultants, end users (pharmaceutical companies), and academia. The group is currently preparing document templates useful for supporting qualification of different standard and non-standard equip- ment. Background Most equipment currently available on the market is the result of a very long and uninter- rupted improvement process that started many years ago and brought to the current design. There is a significant difference between the purchase of a standard system, as opposed to the development of a bespoke or custom made equipment. Pharmaceutical users in most cases are just buying and installing standard pieces of equipment. The design of new parts or new functionality is often negligible, or limited to a small part of the pro- cess. Nonetheless, us- ers are currently spend- ing significant human efforts and financial resources in commis- sioning and qualifica- tion activities that are sometimes excessive and redundant, quite of- ten including a mere repetition of verifica- tions already performed by the manufacturer. Figure 1. Standard equipment development Life Cycle. On-Line Exclusive Article PHARMACEUTICAL ENGINEERING ® The Official Magazine of ISPE May/June 2007, Vol. 27 No. 3

DeCaris2007_RiskBasedEquipQual

Embed Size (px)

DESCRIPTION

This article presents an efficient cooperative approach to Commissioning and Qualification for manufacturing equipment and covers the entire life cycle for the specification, design, manufacture, installation, commissioning, qualification, operation, and maintenance of the equipment in a risk-based approach.

Citation preview

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 1www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    This article presentsan efficientcooperativeapproach toCommissioning andQualification (C&Q)for manufacturingequipment andcovers the entire lifecycle for thespecification, design,manufacture,installation,commissioning,qualification,operation, andmaintenance of theequipment in a risk-based approach.This article reflectsthe current status ofthe work in progressconducted by theGAMP ItaliaEquipment ValidationWorkgroup. Themain topics coveredin the article are:

    holistic risk-basedapproach coveringbusiness, safety,and quality risks

    involvement ofthe supplier in therisk managementprocess and riskanalysis

    support from thesupplier in theC&Q activities(risk-based)

    team building time savings trends good engineering

    practice

    Risk-Based Equipment Qualification:A User/Supplier Cooperative Approach

    by GAMP Italia - Equipment Validation Workgroup:Sandro De Caris, Marco Bellentani, Beny Fricano,Carlo Bestetti, Marco Silvestri, and Barbara Testoni

    GAMP Italia andEquipment Validation Group

    GAMP Italia is a local Community ofPractice that was introduced to theISPE community in December 2005,during the ISPE Milan Conference.The mission of GAMP Italia is to improve

    the communication among users, suppliers,consultants, regulatory authorities, andacademia, helping life sciences companiesstreamline their validation processes througha more consistent application of good practicesand the GAMP guidance on both the suppliersand users side.

    GAMP Italia operates in accordance withthe general objectives of the InternationalGAMP Forum and reports to the GAMP Eu-rope Steering Committee, like other regionalgroups (GAMP Nordic, GAMP D-A-CH, and

    GAMP Francophone).The Equipment Validation Group is the first

    working group started within GAMP Italia andis composed of members coming from equip-ment manufacturers, consultants, end users(pharmaceutical companies), and academia.

    The group is currently preparing documenttemplates useful for supporting qualification ofdifferent standard and non-standard equip-ment.

    BackgroundMost equipment currently available on themarket is the result of a very long and uninter-rupted improvement process that started manyyears ago and brought to the current design.

    There is a significant difference between thepurchase of a standard system, as opposed tothe development of a bespoke or custom

    made equipment.Pharmaceutical usersin most cases are justbuying and installingstandard pieces ofequipment. The designof new parts or newfunctionality is oftennegligible, or limited toa small part of the pro-cess. Nonetheless, us-ers are currently spend-ing significant humanefforts and financialresources in commis-sioning and qualifica-tion activities that aresometimes excessiveand redundant, quite of-ten including a mererepetition of verifica-tions already performedby the manufacturer.

    Figure 1. Standardequipment developmentLife Cycle.

    On-Line Exclusive Article

    PHARMACEUTICAL ENGINEERINGThe Official Magazine of ISPE

    May/June 2007, Vol. 27 No. 3

  • Risk-Based Equipment Qualification

    2 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    Inefficiencies also arise from the variable formulation ofdifferent requirements (from different users) for the manu-facture of the same standard equipment (from the samesupplier). This may easily lead to different validation ap-proaches and sometimes to very different set of documents onbehalf of the supplier. A more uniform approach and a risk-based definition of the requirements can result in a signifi-cant savings in time and effort spent for both parties.

    Risk-based qualification can improve quality andreduce validation efforts. ISPE is actively suggesting thisapproach, which is now being used more and more exten-sively.8,9

    Risk management can be significantly enhanced with thesupplier support, because they have a deep knowledge of thesystems they produce. This approach can ensure faster,cheaper, more complete, and reliable results.

    Indeed, C&Q activities can be significantly abbrevi-ated when the supplier is involved since the earlystages of the process and the efforts done during theproduct development and subsequent manufacturing aretaken into account.

    The main objective of the Equipment Validation WorkingGroup operating within GAMP Italia is to suggest a moreprofitable role of the supplier during the entire equipmentlife cycle from specification and purchase, through manufac-ture and delivery, commissioning and qualification, use,maintenance, and even retirement.

    Considering the current high level of automation in theindustry, it is important to look at computerized systemsand process control software, either embedded or stand-alone related with the equipment. The importance of com-puter control systems is emphasized because in some cases,the equipment is completely dependent on the proper behav-ior of the software. Computer systems may include PLC ormicrocontrollers and Human-Machine Interface (HMI), su-pervisory PC (e.g., SCADA systems, statistical process con-trol), as well as interfaces with other remote systems likeManufacturing Execution System (MES).

    Therefore, the discussion includes both computer valida-tion and equipment qualification in an integrated approach.

    More complex and potentially GxP critical scenarios areon the horizon due to the emerging Process AnalyticalTechnology (PAT) applications that may bring new com-puter systems operating in strict connection with the equip-ment to ensure product quality. The proper identification andmanagement of Critical to Quality Attributes and the rel-evant Critical Process Parameters may significantly helpdevelop a PAT-ready equipment and extend the ICH Q8Design Space concept into the equipment process variables.10

    Basic ConceptsGood practices help ensure high quality products.Properly designed and manufactured products are safe, ro-bust and reliable, well documented; therefore, they should beeasy to qualify and/or validate.This is true for both pharmaceutical products and the equip-ment used to manufacture the products.

    Commissioning, qualification, and validation activitiesare only the final stage of a long process, and can be moreeasily and successfully performed if the entire developmentlife cycle of the equipment is considered, supporting bestpractice and the concept of Quality by Design (QbD) whenthese are pursued by the manufacturer of the equipment.This approach closely relates to good engineering practice,which is endorsed by the ISPE Baseline Guide on Commis-sioning and Qualification.8

    There is a strict similarity between GEP and GMP: in bothcases, quality should be achieved by design, and not justtested at the end of the process. Embedding quality into anequipment design is mostly a suppliers responsibility in acooperative and trustworthy relationship with the user.

    A risk-based approach requires the identification ofcritical items, distinguishing them from ordinary items,and dealing with them in a differentiated manner. Criticalitymay refer to different aspects of the product or process:quality, safety, and business being the most common areas ofinterest.

    Critical items and key documents should be identifiedfrom the beginning of the project (i.e., explicitly documentedin the User Requirements Specification), properly traced tostandard offerings of the supplier and managed during thedesign and manufacture of the equipment, and then carefullyverified during C&Q in a conscious and efficient manner.C&Q should concentrate on critical items, according to asound risk evaluation methodology, and following a struc-tured risk management process.

    Standard, non-critical parts (e.g., non contact parts, func-tionality with no or little impact on product quality) can beimplicitly qualified during manufacturing if the supplier iscapable of demonstrating suitable maturity in the designand manufacturing. Verifications performed during FAT andSAT can be used as a proof of the good design and goodmanufacture, without the need of repeating the same testsover and over.

    The expertise and knowledge of the supplier and theactivities performed during manufacturing should be used toavoid redundancy.

    Development Life CycleA practical risk-based approach should consider the real lifecycle of the product development (as opposed to the lifecycle in the delivery of a single instance of the standardequipment). Most manufacturers today have very standardequipment, designed for a large market and highly modular.This is quite common for instance with automatic machineslike capsule fillers and tablet presses, and packaging lines,etc. The design of the equipment for a single customer islargely a matter of choosing the right model and assemblingtogether the appropriate optional parts. Practicing good en-gineering practice is largely sufficient to qualify many ele-ments of standard equipment.

    Equipment CategoriesTo simplify the management of equipment qualification/

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 3www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    validation, it may be useful to distinguish the following mainclasses of equipment:

    standard equipment with no configurable parts or func-tions

    standard configurable equipment, having two possiblelevels of configuration:- definition of which standard parts are to be included- setting of parameters for the parts included

    custom or bespoke apparatus (prototypes of new equip-ment, custom built) specifically developed by the supplierto meet a set of specified user requirements

    Standard configurable equipment may contain some customparts that should be identified and treated as bespoke appa-ratus.

    Development vs. ConfigurationThe development of new products (standard equipment)follows a complex life cycle, normally defined in the suppliersQuality Management System. A good reference is the Vmodel included in GAMP Guide.2

    The product is released on the market following an incre-mental life cycle with many different releases during theproduct life span. The entire process, limited to softwareportion for simplicity, may be summarized in Figure 1.

    The large variety of customer requirements results in avery high level of modularity within the same equipment.Different models, different optional units, and a large amountof variable parameters are normally available in a standardequipment.

    A new version of the equipment and/or its relevant controlsoftware is delivered to the Customer only when the develop-ment process has been completed. This includes the manage-ment of functional and technical specifications, and theexecution of all defined test cases. New custom (bespoke)functions may become part of the evolving standard.

    Therefore, the standard product development line is or-thogonal to the configuration process, needed to tailor thegeneral product to the customer specific requirements.

    Software for a single piece of equipment is quite oftenupgraded during the operation period, even long after thestart-up, for instance when new products are to be manufac-tured. The life cycle for the delivery of a single system from acombined user and supplier viewpoint can be seen in Figure2.

    The knowledge of the actual product life cycle and thedifferentiation between the management of standard partsvs. bespoke parts is fundamental for an appropriate riskmanagement.

    A Holistic Risk Management ApproachRisks may arise in different areas:

    Quality

    Safety Business

    Product Quality Aspects (GxP)In this case, what matters in the pharmaceutical industry isthe quality of the final product delivered to the patient. In thisarea, all GxP requirements are included. The quality hazardimpact can be evaluated according to:

    damage to patient (illness, temporary or permanent sideeffects, death)

    Figure 2. Delivery life cycle for a specific user.

  • Risk-Based Equipment Qualification

    4 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    compliance issues with the authorities

    Typically, quality aspects are identified by Critical to QualityAttributes (CQAs) for the product.

    Safety Aspects (Operator and Environment)In this case, what matters is the evaluation of the potentialdamage to the personnel operating the equipment and/or theimpact on the environment caused by system malfunctions.The safety hazard impact can be evaluated according to:

    damage to personnel (temporary or permanent injury,death)

    damage to the environment (damage to people who liveoutside the factory)

    Business AspectsIn this case, what matters is the evaluation of the potentialdamage for the business caused by system malfunctions orlack of availability. The business hazard impact can beevaluated according to:

    cost of components to be replaced and workmanship (di-rect damage)

    production loss (indirect damage)

    Business continuity, line efficiency, down time, size changeover, and line set-up are important items in this perspective.

    A description of an overall risk management process isshown in Figure 3.

    Risk AnalysisThe results of the analysis depends largely on the impact thatthe customer assigns to each identified source of risk. Thesame function could be potentially critical in a specific appli-cation and non-critical in a different one. Cooperation be-tween customer and supplier is essential to properly managerisks.

    User - Supplier CooperationThe supplier can provide a large number of support activitiesand services during the life cycle of a product, under all thedifferent perspectives, offering a significant contribution inthe risk management process.

    A general risk management flow can be adopted. ICH Q9established a standard approach for Quality Risk Manage-ment that is quite general and can be easily adopted for allthree areas.

    Figure 3. Overall risk management flow chart.

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 5www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    Involvement of the supplier in the process can include alarge part of the risk analysis, provided it is based on theinformation supplied by the user.

    In more detail, the sequence of operations can be seen inFigure 4.

    The flow of operation also illustrates the embedded RiskCommunication process between user and supplier along theentire life cycle, and their different role and responsibility inthe risk management process. The following three mainphases can be distinguished:

    1. Specification Phase. Its the responsibility of the user tocommunicate potential risks and the relevant impact tothe supplier so that important items are properly man-aged during design and manufacturing of the equipment.The supplier should be made aware of unwanted issuesimpacting the quality of the product, the safety of theoperators and the business, and the relevant impact level.

    2. Design and Manufacture Phase. Its the responsibilityof the supplier to identify critical parts (such as mechani-cal units, components, software functionality, or param-eters) and communicate these to the user. The user canthen wisely evaluate the risks and provide additionalcontrols or countermeasures where necessary, and finallyaccept the system design when residual risks are below anacceptable threshold.

    3. Operation Phase. The operation and maintenance of theequipment should be performed in cooperation with thesupplier to maintain constant performances over the timeand/or improve the system when necessary.

    It should be noted that while the technical part of the riskanalysis can be performed by the supplier, its a re-sponsibility of the user to evaluate the risks, to provideany required additional controls, and finally to acceptthe residual risks. This possible separation of roles hasbeen clarified in ICH Q9.16

    Its important to distinguish between elements critical-ity and process (residual) risk: an element (system compo-nent or function) may be critical because it guarantees theproduct quality, nonetheless, the residual risk for the processcan be low due to the high reliability of the element.However, irrespective of the residual risks, critical partsshould be identified because they need qualification/valida-tion.

    Standard parts exhibit less risks than custom parts andfunctions. Under a risk perspective, the explanation is intheir improved reliability and lower probability of failure(while the impact remains unchanged).

    When the risk analysis is conducted purely for compliancepurposes (e.g., to define qualification/validation activities), itcan be performed at a high level, without entering into systemdetails such as analysis at component level.

    When the risk analysis is required to investigate on

    specific quality hazards or to cover safety and business risks(e.g., reliability of the equipment), additional difficultiesarise on the users side: the user doesnt have sufficientinformation and knowledge about the system and the analy-sis can be very labor intensive and time consuming. One ofthe difficult items to characterize the system is the prob-ability of occurrence for adverse events since these are quiteoften related to system components reliability. The manufac-turer on the other hand has the necessary knowledge, canguarantee an investigation with sufficient level of detail, andcan afford an investment of time and resources on a productthat is intended for a wide market and not only for a singleuser.

    Its worth observing that risk analysis performed by thesupplier should be somewhat parametric. The results shouldin fact be tailored to the specific list of hazards and theirimpact level, as communicated by the user during the speci-fication phase.

    Validation Life CycleBased on the Equipment Validation Group experience, thefollowing are preliminary recommendations on the entire lifecycle of a generic piece of equipment. Further and morespecific suggestions will be included directly in the dedicateddocuments the group will produce in the future for eachequipment type.

    The Equipment Validation Group is preparing documenttemplates useful for reducing the time and efforts in theentire delivery process, including C&Q. Templates are pro-duced in an industry wide perspective and include sugges-tions for tailoring the document to the specific applicationcase.

    The group realizes that producing standard documents isnot always possible considering the variety of different me-chanical, electrical, and software solutions available on themarket. Where a general template cant be produced, thegroup will prepare a guide for the preparation of the docu-ment.

    User RequirementsTo properly implement a holistic risk-based approach, it isnecessary to start defining critical items from the beginningof the process. The user should provide the supplier with theidentification of different hazards (quality, safety, and busi-ness) and the relevant impact evaluation.The following are some specific suggestions:

    The User Requirements Specification (URS) should betreated as a contractual document, avoiding conflicts withother technical specification documents. The URS shouldnot be considered a mere part of the validation documen-tation, but rather the main - and possibly only - specifica-tion document for the equipment.

    Ideally, the requirements should be independent from thesuppliers product and express customer needs withoutaddressing specific design solutions.

  • Risk-Based Equipment Qualification

    6 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    Figure 4. User-supplier cooperation scheme.

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 7www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    The URS should, as a minimum, cover all mandatoryparts, including those necessary to guarantee the finalproduct quality and achieve compliance with the rules.One often neglected part is the definition of the expectedquality of the product and the level of allowance forunwanted defects.

    Requirements on equipment safety and business perfor-mances also should be included.

    Detailed technical requirements which are typically pro-duced by the user may be included if appropriate in anannex of the URS, as this document usually specifiesdesign solutions rather than equipment performances.

    Ideally, all requirements should be identified with a uniquecode for easy and unambiguous traceability and classifiedaccording to the impact. If possible, impact should bedefined in more than one level (e.g., high/medium/low).Business requirements should be classified according totheir priority (e.g., mandatory or nice to have.)

    Generic requirements like the software shall be 21 CFRPart 11 compliant should be avoided. High level identifi-cation of GxP critical data which are expected to behandled by the system should be done at this stage of theprocess.

    The main issue for the customer during the requirementphase is to identify the most appropriate supplier and themost appropriate equipment model that can satisfy all therequirements.

    Validation PlanThe Validation Plan should be developed by the user consid-ering the actual life cycle of the manufacturer that changessignificantly depending on the amount of design activities

    required to deliver the equipment. Efforts should be based onthe overall risk scenario, thus, considering on a global level,aspects related to standard components, supplier, and prod-uct maturity.

    Overall Risk ScenarioProduct and supplier maturity should be evaluated. A goodguide is provided in the GAMP Good Practice Guide: Testingof GxP Systems;6 - Figure 5.

    Supplier MaturityThe supplier maturity should be evaluated with a detailedanalysis of the design, manufacturing, and support processesof the supplier. The supplier audit is the best tool to achievethis goal and its an important part of the process. To facili-tate sharing and comparison of information, the use of stan-dard checklists is highly recommended, such as the oneproposed in the Appendix M2 of the GAMP Guide.3

    Re-use of previously performed supplier audits is encour-aged, especially within large organizations, thus, avoidingrepetitions and redundancy. A secrecy agreement with thesupplier may be necessary.

    Product MaturityProduct maturity should be carefully evaluated, consideringthe level of standardization achieved for the specific equip-ment. This may require an investigation with the supplier,and a standard survey may prove useful when selectingamong different suppliers. Standard and robust productsshould be preferred to custom solutions, unless strictly nec-essary. Custom (bespoke) systems normally exhibit muchhigher risks and should be handled with extra care.

    Functional SpecificationsFunctional Specifications (FS) are documents commonly pro-duced by the manufacturer. FS for a standard equipment canbe structured in a standardized validation package thatoften includes Design Specification (DS), plus InstallationQualification (IQ) and Operational Qualification (OQ) proto-cols - Figure 6.

    The main issue here is to map variable User Require-ments with standard elements (components or functionalities)of the equipment. This is normally done by the supplierduring the User Requirements evaluation phase. Differentsituations may arise when analyzing each User Require-ment:Figure 5. GAMP GPG: Testing of GxP Systems (Figure C1.1:

    Supplier and Product Maturity Model - Chapter. 1: Minimizing UserTesting).

    Figure 6. Standard vs. specific documentation.

  • Risk-Based Equipment Qualification

    8 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    1. The requirement can be satisfied with a standard basicelement.

    2. The requirement can be satisfied with an optional ele-ment.

    3. The requirements involves the re-design of an existingelement.

    4. The requirement involves the design of a new element.

    Cases 1 and 2 are very similar: the main difference isgenerally only at the commercial level, and both can beconsidered as standard equipment.

    Case 3: The re-design should be managed by the supplierunder strict change control and the decision should be madeto include the change in the standard product or consider thisas a customer specific (bespoke) difference. Bespoke compo-nents are highly discouraged in the development of standardequipment, but this may be the only way forward.

    Case 4: New parts can be designed on demand and still beincluded in the standard product life cycle, but the risk maybe higher for the first installations. Software is normallymanaged as a standard product, typically highly configurablewith many parameters.

    To ensure traceability with the User Requirements, eachsingle Functional Specification should be identified with aunique code.

    Traceability MatrixProducing a Traceability Matrix (TM) is very important forC&Q activities. It can help to trace all user requirements,thus, ensuring both complete coverage of URS and testcoverage of the critical functions.

    Following the GAMP suggestions, TM should report thecriticality level of each function. This can help the quickidentification of critical functions. Safety and/or businesscritical functions also should be properly identified in the TMto achieve a holistic system criticality understanding.

    In addition to the recommendations from the GAMPGuide,4 additional information should be included in the TMregarding the level of standardization of the function. Higherrisk non-standard functionality can be quickly located in thisway.

    Design SpecificationsDesign specifications for standard equipment should de-scribe the equipment, rather than fit specific User Require-ments. The main purpose of the documentation is to providethe user with useful information for the operation and main-tenance of the equipment. Normally, the supplier is able todemonstrate traceability between standard DS and the rel-evant standard FS. This traceability also may be included inthe standard Qualification/Validation Package.

    However, design solutions that are arranged specificallyfor the user should be identified. Non-standard solutionsshould be managed with additional care and specific details,especially when they cover critical aspects of the system.

    The supplier should provide all the required documentsfor the parts included in the final equipment. As-built docu-

    mentation (such as electrical, lubrication, and pneumaticdiagrams) is commonly available from the supplier.

    Additional documents may be contractually agreed be-tween the user and the supplier in the technical annex of theURS.

    Risk Analysis (and/or Risk Management Plan)The supplier may play a very important role in the riskmanagement process. This has already been covered in thediscussion A Holistic Risk Management Approach.

    Under the modern approach of ICH Q9, the risk manage-ment concepts along the entire life cycle should replace thepure risk analysis performed in a single phase. Therefore, itis recommended to prepare and follow a Risk ManagementPlan, rather than a single Risk Analysis document.

    It should be remembered that according to the spirit ofICH Q9, risks should be carefully evaluated by the user andresidual risks formally accepted.

    Before starting the risk analysis process, it is essential toestablish the scope: to either evaluate only the quality as-pects and define the validation approach, or also to coversafety and business aspects.

    In the first case, the risk analysis can be efficientlyperformed by the user, adopting a top-down technique likeFault Tree Analysis (FTA) to cover specific product qualityrelated risks.

    In the latter case, risk analysis should be more detailedand cover system components. This is in general a complexand time consuming exercise that can be effectively per-formed by the supplier using a bottom-up technique likeFailure Mode and Effects Analysis (FMEA). This approachalso helps with preparing the list of critical items (GxP,safety, business). Making this information available to theuser is an important part of the risk communication process.

    Equipment Construction, Commissioning andQualificationSignificant savings can be achieved if efforts are focused oncritical items of the equipment and the results of previoustesting phases - Figure 7.

    Check-Out TestingConsolidated software versions installed on each equipmentare tested by the manufacturer according to the developmentlife cycle.

    The check-out internal testing phase at the supplierspremises has the purpose to ensure that the equipment isproperly built and functioning in all of its components (me-chanical, electrical, electronic, and software) and that itsatisfies the specific user requirements provided by thecustomer. The focus of testing activities before the delivery ofa standard equipment to a specific user is the proper configu-ration (selection of items and parameters that satisfy theuser requirements), and proper integration in the equip-ment. These testing activities can be optimized. For instance,if a software algorithm has already been tested during thedevelopment process, it is not always necessary to include it

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 9www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    in the check-out.Quite often the equipment check-out is ignored during the

    subsequent steps of the commissioning and qualification,while the evidence of these tests could provide sufficientinformation and avoid test redundancy.

    FATA Factory Acceptance Testing (FAT) phase can be executed tocheck congruence of the system to the purchase order and itsproper functioning with the actual customer products. FATsare mainly intended to allow the customer to verify properconstruction and operation of the equipment at the supplierspremises; therefore, authorizing delivery to the users plant.The documentation produced during the FAT may be in partre-used during the subsequent Site Acceptance Test (SAT).

    When the supplier has been properly qualified, a signifi-cant reduction in testing activities can be done. FAT shouldconcentrate on critical items identified in the previous stepsof the process. Testing of standard parts can be evidenced bythe internal test results of the supplier, including the finalcheck-out documents.

    The execution of FAT may be skipped for standard equip-ment produced by well-known suppliers, while the user mayrequire the testing documentation (e.g., final checkout re-sults) before authorizing delivery.

    Commissioning and SATThe supplier normally supports the customer during theinstallation of the equipment, connecting utilities, and per-forming initial installation tests. The usage of standardcheck-lists is highly recommended in this stage.

    When the installation has been completed, a Site Accep-tance Testing (SAT) phase can be executed to verify properoperation of the equipment at the users premises, includinglocal interfaces with other systems. SAT efforts may effi-ciently be reduced re-using the experience and documents

    already produced during the FAT, focusing on parts andfunctions that may be compromised by the disassembling,transport, and reassembling process. The supplier may helpwith indicating which tests are to be repeated at the finaldestination. Testing of non critical parts or functionality mayadequately be covered by the SAT, without any need for aformal qualification. Additional suggestions about the man-agement of commissioning activities can be found in the ISPEBaseline Guide on Commissioning and Qualification.8

    The supplier supports the customer with plenty of docu-mentation that can be used to develop the specific preventa-tive maintenance plan and the calibration plan. Additionalsuggestions can be found in the GAMP Good Practice Guide:Calibration Management.7

    Information from the supplier may be useful to prepare:

    training SOPs business continuity/disaster recovery planning maintenance planning and action procedures

    Qualification: IQ, OQ, and PQIQ, OQ, and PQ activities should be limited to systems andcomponents with Direct Impact on the product quality. All ofthe rest of the system may be simply commissioned andmanaged according to good engineering practice. The identi-fication of critical parts is an outcome of the Risk Analysis.

    IQ and OQ may be easily conducted using the standardQualification/Validation Package normally available fromthe supplier, covering the majority of physical and functionalfeatures of the equipment. This documentation should beproduced in accordance with a sound risk-based approach.The execution of IQ and OQ tests may be accelerated with thesupport of the supplier, especially when using its documentset. However, specific URS and relevant Critical ProcessParameters also should be addressed by IQ and OQ withadditional tests to be integrated into or enclosed to thesupplier standard package. The responsibility of the qualifi-cation testing is still with the user who should review andapprove the documents and witness the execution of the tests.Repetition of tests already performed during equipmentcheck-out, FAT or SAT is normally redundant and should beperformed only when the previous tests can be compromisedby other activities.

    PQ is more specific for the customer application and somelevel of tailoring from a standard template is quite oftennecessary. The supplier may optionally contribute in thepreparation of this document as well as support the executionof the relevant tests.

    TrainingTraining is another important part of the commissioning andqualification phases. Specific sessions for the different rolesinvolved in the usage of the equipment should be designed bythe supplier in order to explain the right things to the rightpeople. The supplier should prepare a suitable risk-basedtraining package with specific instructions about the man-

    Figure 7. Testing activities.

  • Risk-Based Equipment Qualification

    10 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    agement of GxP and safety risks.

    On-Going System OperationOnce the equipment is in production, there are still severalopportunities for the customer and supplier to keep on thepositive cooperative relationship created during the start-up.

    The supplier may support the user to perform most criticaland complex maintenance checks and operations with spe-cific frequencies.

    In addition to these maintenance interventions, the usershould periodically review and evaluate the system perfor-mances.

    As a result of this analysis, the user may decide to performa periodic revalidation repeating a subset of IQ/OQ testscovering the components and features with higher criticalitylevel in order to demonstrate that the system maintains itsvalidated state. The supplier can still support the customer toidentify appropriate tests and execute them more rapidly.

    Other services that the supplier can provide during thelife-time of the equipment cover the following aspects:

    specific training sessions to new people involved in theequipment operation

    software and/or hardware upgrade and relevant qualifica-tion activities (typically performed to comply with up-dated regulations, to renew obsolete components, or toadopt improvements applied to the product installed ondifferent equipments)

    warranty services extraordinary maintenance interventions support for equipment relocation from one site to another

    DecommissioningThe supplier may support the user even in the final stage ofthe equipments life. At system retirement, it may be neces-sary to safeguard important information that is kept in thesystem, because the mere backup or recovery procedurescould not fit for data migration to a new, different, equipment.The supplier role, in the case, may be helpful in many aspects,including managing obsolete mass storage devices or codingspecific software filters.

    Quality AuditsThe customer may increase his confidence in the supplierduring the life cycle: by means of quality audits performed onthe development process, periodically inspecting the supplierduring the construction phases, controlling check-out resultsduring FAT, and finally during the installation and qualifica-tion phases.

    The mature supplier uses the results of audits,verifications, and inspections in a pro-active philoso-phy as drivers for continuous improvement.

    Developing standard products, both the supplier and theequipment progressively increase their maturity level, goingtoward the preferred solution where customer verificationsmay be reduced in terms of frequency and rigour - Figure 5.

    Trust is based on the confidence on the supplier qualitysystem and the overall design and manufacturing processesthat bring to the final equipment.

    ConclusionsTo save time and money in the commissioning and qualifica-tion activities still guaranteeing the final proper quality levelof the equipment and the relevant production, it is basilar touse a risk-based approach that focuses on critical items of theequipment and critical activities of the life-cycle.

    The knowledge of the actual manufacturing life cycle mayaid in the identification of critical steps in the process,distinguishing the production and assembling of standardparts from the design of custom parts.

    Supplier involvement from the early stages of the processcan further improve savings. Building a trustworthy rela-tionship between the user and supplier can reduce redundan-cies and provide significant advantages for both parties.

    C&Q efforts can be significantly reduced using matureproducts and mature suppliers. Using best practices in thedesign and manufacturing bring the mature supplier closerto the sphere of Quality by Design, improving their productsand services.

    GlossaryC&Q Commissioning and QualificationCQA Critical to Quality AttributeDS Design SpecificationFAT Factory Acceptance TestFMEA Failure Mode and Effects AnalysisFS Functional SpecificationsFTA Fault Tree AnalysisGAMP Good Automated Manufacturing PracticeGEP Good Engineering PracticeGMP Good Manufacturing PracticeGPG Good Practice GuideHMI Human Machine InterfaceIQ Installation QualificationMES Manufacturing Execution SystemOQ Operational QualificationPAT Process Analytical TechnologyPLC Programmable Logic ControllerPQ Performance QualificationQbD Quality by DesignSAT Site Acceptance TestSCADA Supervisory, Control, and Data AcquisitionSOP Standard Operating ProcedureTM Traceability MatrixURS User Requirements Specification

    References1. GAMP 4 Good Automated Manufacturing Practice

    (GAMP) Guide for Validation of Automated Systems,International Society for Pharmaceutical Engineering(ISPE), Fourth Edition, December 2001.

  • Risk-Based Equipment Qualification

    MAY/JUNE 2007 PHARMACEUTICAL ENGINEERING On-Line Exclusive 11www.ispe.org/PE_Online_Exclusive

    Cop

    yrig

    ht IS

    PE 2

    007

    2. GAMP 4 Good Automated Manufacturing Practice(GAMP) Guide for Validation of Automated Systems,International Society for Pharmaceutical Engineering(ISPE), Fourth Edition, December 2001, Chapter 6 Vali-dation Overview.

    3. GAMP 4 Good Automated Manufacturing Practice(GAMP) Guide for Validation of Automated Systems,International Society for Pharmaceutical Engineering(ISPE), Fourth Edition, December 2001, Appendix M2Guideline for Supplier Audit.

    4. GAMP 4 Good Automated Manufacturing Practice(GAMP) Guide for Validation of Automated Systems,International Society for Pharmaceutical Engineering(ISPE), Fourth Edition, December 2001, Appendix M5Guideline for Design Review and Requirements Trace-ability Matrix.

    5. GAMP Good Practice Guide: A Risk Based Approach toCompliant Records and Signatures International Societyfor Pharmaceutical Engineering (ISPE), First Edition,April 2005.

    6. GAMP Good Practice Guide: Testing of GxP Systems,International Society for Pharmaceutical Engineering(ISPE), First Edition, December 2005.

    7. GAMP Good Practice Guide: Calibration Management,International Society for Pharmaceutical Engineering(ISPE), First Edition, December 2001.

    8. ISPE Baseline Pharmaceutical Engineering Guide, Vol-ume 5 - Commissioning and Qualification, InternationalSociety for Pharmaceutical Engineering (ISPE), FirstEdition, March 2001.

    9. A White Paper on Risk-Based Qualification for the 21st

    Century, ISPE, 9 March 2005.10. Branning, R., et al., Quality by Design, Validation, and

    PAT: Operational, Statistical and Engineering Perspec-tives, Pharmaceutical Engineering, Vol. 26, No. 6, 2006,pp.

    11. US FDA - Code of Federal Regulations, Title 21, part 210:Current Good Manufacturing Practice in Manufacturing,Processing, Packaging, or Holding of Drugs; General.

    12. US FDA - Code of Federal Regulations, Title 21, part 211:Current Good Manufacturing Practice for Finished Phar-maceuticals.

    13. US FDA - 21 CFR Part 11: Electronic Records; ElectronicSignatures - Final Rule.

    14. European Commission, The Rules Governing MedicinalProducts in the European Union Volume 4: Good Manu-facturing Practices Medicinal Products for Human andVeterinary Use, Annex 11 Computerised Systems; An-nex 15.

    15. PIC/S Guidance: Good Practices for Computerised Sys-tem in Regulated GxP Environment, Document PI 011-2(July 2004).

    16. ICH Q9 - Quality Risk Management (step 4, approved Nov2005).

    About the AuthorsGAMP Italia Equipment Validation WorkgroupThe working group has a Steering Committee, active mem-bers, and associate members. The following list includes onlythe members of the group who authored the article.

    Sandro De Caris is an IT Compliance Con-sultant for the life sciences industry, sup-porting both manufacturers and suppliers.His expertise covers computer systems vali-dation, GxP compliance, risk management,and PAT. He graduated in electronics engi-neering and has more than 20 years of expe-rience in the pharmaceutical industry at the

    international level, operating in hardware and softwaredesign, software quality assurance, computer validation,project management, and company management. Beforemoving into a freelance profession, his last role was manag-ing director of a leading Italian company specialized incompliance and validation; a subsidiary of an internationalIT company based in the UK. De Caris is currently chairmanof GAMP Italia and coordinates the Equipment ValidationWorkgroup. He can be contacted by telephone at: +39 0516516945 or by e-mail at: [email protected].

    IT Compliance and Validation Consultant, Via Giardino,60, 40065 Pianoro, Bologna, Italy.

    Marco Bellentani graduated in computerscience at the University of Bologna, joinedMG2 in 1993 as a software engineer, and for11 years has held a position of SoftwareProjects Leader and Product Manager withparticular focus on quality assurance, vali-dation, standards, and methodologies defini-tion. GAMP, GxP, risk management, elec-

    tronic records and signatures have been some of the qualityand regulatory aspects experienced during these years. In2005, Bellentani joined the Quality Assurance Departmentas Validation Manager and Software Quality AssuranceManager. In this role, he defines validation, training anddocumentation policies and software development standards,conducts Supplier quality audits required by customers, andfollows internal projects for process optimization. He also isthe coordinator and project quality assurance of MG2 PATTeam, a group of experts supporting customers in the imple-mentation of practical PAT solutions, and in this role, heattends to pharmaceutical meetings both as a speaker and asan attendee. Since the beginning of 2006, he has been amember of MG2 Executive Board involved in the definitionand supervision of MG2 strategies for the future. He can becontacted by telephone at: +39 051 4694 111 or by e-mail at:[email protected].

    MG2 S.r.l., via del Savena, 18, I-40065 Pian di Macina diPianoro, Bologna, Italy.

  • Risk-Based Equipment Qualification

    12 PHARMACEUTICAL ENGINEERING On-Line Exclusive MAY/JUNE 2007 www.ispe.org/PE_Online_Exclusive

    Copyright IS

    PE 2007

    Beny Fricano graduated in electronics en-gineering at the University of Ferrara. Since2001, he has been involved in software qual-ity assurance and qualification and com-puter system validation at I.M.A., a companyengaged in the design and manufacture ofpackaging machinery and Systems for bothpharmaceutical and alimentary products.

    Fricano has been an ISPE member since 2005. He is involvedas active member of the Gamp Italia (Equipment ValidationWorkgroup). He can be contacted by telephone at: +39 0516514999 or by e-mail at: [email protected].

    IMA SpA, I.M.A. Industria Macchine Automatiche, ViaEmilia 428/442, 40064 Ozzano dellEmilia, Bologna, Italy.

    Carlo Bestetti is a consultant in computersystem validation and compliance. With aneducational background in classical studiesand a degree in mechanical engineering c/oPolitecnico di Milano, his working life hasbeen spent in application fields such as me-chanics, electronics, petrochemistry, energyin engineering companies, production com-

    panies, plant maintenance, and validation services touchingevery aspect of automation engineering. Bestetti shares hisexperience by tutoring on the job, publishing articles, pre-senting papers at international congresses, and has obtainedpatents. He is an active member of Gruppo ImpreseStrumentazione Italia (GISI) and Associazione Italiana perlAutomazione (Anipla). He joined ISPE in 1995 as member ofthe Italian Affiliate Steering Committee, and in 1996, hereceived an ISPE special Award. Bestetti is now active in theGAMP COP. He can be contacted by telephone at: (+39) 03924 96 855 or by e-mail at: [email protected].

    Compliance and Automation Validation Consultant, ViaRamazzotti, 11, I-20052 Monza, Milano, Italy.

    Marco Silvestri received the Laurea De-gree in mechanical engineering from theUniversity of Parma, Italy in 1999. Aftercollaborating with the Industrial Engineer-ing Department of the same university, hewas employed as researcher by Computess.r.l. (Niviano di Rivergaro, PC), a softwarehouse that produces CAD/CAM for mechani-

    cal industry. During 2001-2002, he was head of research anddevelopment of Tecnomec s.r.l. (Vignola, MO), a manufac-turer of machines and plants for the meat industry. In thisrole, he developed innovative solutions for plants of Campofrio(Burgos, Spain) and Rovagnati (Biassono, Italia). Silvestrialso was involved in vision system projects for industrialautomation, collaborating with Vicivision s.r.l. (Fidenza, PR)on developing automated control machines for pharmaceuti-cal (GlaxoSmithKline) and medical device (B.Braun) indus-tries. Since October 2002, he has held the position of Assis-tant Professor at University of Parma, lecturing on actuatorsmechanics at the mechanical engineering laurea degree, on

    mechatronics at the mechanical engineering laurea magistraledegree, and Packaging mechanics at Food Industry Mechani-cal Engineering laurea magistrale degree. He can be con-tacted by telephone at: +39 0521 90 5700 or by e-mail at:[email protected].

    Universita degli Studi di Parma, Dipartimento diIngegneria Industriale Pal., 8 Viale G.P. Usberti 181/A 43100,Parma, Italy.

    Guerrina Barbara Testoni is a ProjectManager and Executive Consultant withAdeodata, Italy. She has a degree in math.Prior to join Adeodata, she was the R&D ITDevelopment Area Manager with ChiesiFarmaceutici. Testoni has more than 16 yearsof experience in the pharmaceutical industryspecializing in computer system validation,

    information system implementation and management, sys-tem integration, and business process reengineering of vari-ous systems such as: LIMS, EDMS, eSubmission, CDMS,Drug Safety, Clinical Database, ERP. She can be contacted bytelephone at: +39-338-8426687 or by e-mail at: [email protected].

    Adeodata, Via Grigne, 5, I-20020 Lazzate, Milano, Italy.